Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.
Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Müller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD. Borner MM, et al. Among authors: brauchli p. J Clin Oncol. 2002 Apr 1;20(7):1759-66. doi: 10.1200/JCO.2002.07.087. J Clin Oncol. 2002. PMID: 11919232 Clinical Trial.
Exemestane seems to stimulate tumour growth in men with prostate carcinoma.
Bonomo M, Mingrone W, Brauchli P, Hering F, Goldhirsch A; Swiss Group for Clinical Cancer Cancer Research, a member of the Swiss Institute of Applied Cancer Research. Bonomo M, et al. Among authors: brauchli p. Eur J Cancer. 2003 Sep;39(14):2111-2. doi: 10.1016/s0959-8049(03)00486-6. Eur J Cancer. 2003. PMID: 12957469 Clinical Trial. No abstract available.
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.
Borner MM, Bernhard J, Dietrich D, Popescu R, Wernli M, Saletti P, Rauch D, Herrmann R, Koeberle D, Honegger H, Brauchli P, Lanz D, Roth AD; Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland. Borner MM, et al. Among authors: brauchli p. Ann Oncol. 2005 Feb;16(2):282-8. doi: 10.1093/annonc/mdi047. Ann Oncol. 2005. PMID: 15668285 Free article. Clinical Trial.
Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02).
Klaeser B, Nitzsche E, Schuller JC, Köberle D, Widmer L, Balmer-Majno S, Hany T, Cescato-Wenger C, Brauchli P, Zünd M, Pestalozzi BC, Caspar C, Albrecht S, von Moos R, Ruhstaller T. Klaeser B, et al. Among authors: brauchli p. Onkologie. 2009 Dec;32(12):724-30. doi: 10.1159/000251842. Epub 2009 Nov 9. Onkologie. 2009. PMID: 20016233 Clinical Trial.
Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02).
Leupin N, Schuller JC, Solenthaler M, Heim D, Rovo A, Beretta K, Gregor M, Bargetzi MJ, Brauchli P, Himmelmann A, Hanselmann S, Zenhäusern R. Leupin N, et al. Among authors: brauchli p. Leuk Lymphoma. 2010 Apr;51(4):613-9. doi: 10.3109/10428191003624231. Leuk Lymphoma. 2010. PMID: 20218808 Clinical Trial.
Trastuzumab beyond progression: a cost-utility analysis.
Matter-Walstra KW, Dedes KJ, Schwenkglenks M, Brauchli P, Szucs TD, Pestalozzi BC. Matter-Walstra KW, et al. Among authors: brauchli p. Ann Oncol. 2010 Nov;21(11):2161-2168. doi: 10.1093/annonc/mdq250. Epub 2010 May 5. Ann Oncol. 2010. PMID: 20444849 Free article.
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06).
Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, von Moos R, Moosmann P, Montemurro M, Schneider PM, Rauch D, Gautschi O, Mingrone W, Widmer L, Inauen R, Brauchli P, Hess V. Ruhstaller T, et al. Among authors: brauchli p. J Clin Oncol. 2011 Feb 20;29(6):626-31. doi: 10.1200/JCO.2010.31.9715. Epub 2011 Jan 4. J Clin Oncol. 2011. PMID: 21205757 Clinical Trial.
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07).
Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J, Simcock M, Giobbie-Hurder A, Berthod G, Genton C, Brauchli P, Aebi S; Swiss Group for Clinical Cancer Research (SAKK). Zaman K, et al. Among authors: brauchli p. Ann Oncol. 2012 Jun;23(6):1474-81. doi: 10.1093/annonc/mdr448. Epub 2011 Oct 14. Ann Oncol. 2012. PMID: 22003243 Free article.
41 results